Mustang Bio Inc Market Cap ($2.76 Million)
Market Cap & Net Worth: Mustang Bio Inc (MBIO)
Mustang Bio Inc market cap. Mustang Bio Inc (NASDAQ:MBIO) has a market capitalization of $2.76 Million ($2.76 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29600 globally and #6048 in its home market, demonstrating a 13.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mustang Bio Inc's stock price $0.41 by its total outstanding shares 6732121 (6.73 Million). Also see how efficiently does Mustang Bio Inc generate cash for how efficiently the company converts equity into cash flow.
Mustang Bio Inc Market Cap History (2017–2026)
Mustang Bio Inc market cap history from 2017 to 2026. Data shows change from $1.21 Billion to $2.76 Million (-47.22% CAGR). Check Mustang Bio Inc (MBIO) stock price for real-time trading data and today's change.
Index Memberships
Mustang Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #850 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2729 of 3165 |
Weight: Mustang Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mustang Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mustang Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Mustang Bio Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MBIO by Market Capitalization
Companies near Mustang Bio Inc in the global market cap rankings as of November 4, 2026. Also see MBIO current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Mustang Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Mustang Bio Inc (2017–2026)
Market capitalization of Mustang Bio Inc from 2017 to today. Between 2017 and today, Mustang Bio Inc's market cap moved from $1.21 Billion to $ 2.76 Million, with a yearly change of -47.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.76 Million | -58.27% |
| 2025 | $6.60 Million | +454.24% |
| 2024 | $1.19 Million | -86.89% |
| 2023 | $9.09 Million | -77.21% |
| 2022 | $39.88 Million | -76.21% |
| 2021 | $167.63 Million | -56.14% |
| 2020 | $382.22 Million | -7.23% |
| 2019 | $412.01 Million | +38.78% |
| 2018 | $296.89 Million | -75.48% |
| 2017 | $1.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Mustang Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.76 Million USD |
| MoneyControl | $2.76 Million USD |
| MarketWatch | $2.76 Million USD |
| marketcap.company | $2.76 Million USD |
| Reuters | $2.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB… Read more